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ABSTRACT
Mouse embryonic stem (ES) cells are a popular
model system to study biological processes, though
uncovering recessive phenotypes requires inactivat-
ing both alleles. Building upon resources from the
International Knockout Mouse Consortium (IKMC),
we developed a targeting vector for second allele in-
activation in conditional-ready IKMC ‘knockout-first’
ES cell lines. We applied our technology to sev-
eral epigenetic regulators, recovering bi-allelic tar-
geted clones with a high efficiency of 60% and used
Flp recombinase to restore expression in two null
cell lines to demonstrate how our system confirms
causality through mutant phenotype reversion. We
designed our strategy to select against re-targeting
the ‘knockout-first’ allele and identify essential genes
in ES cells, including the histone methyltransferase
Setdb1. For confirmation, we exploited the flexibil-
ity of our system, enabling tamoxifen inducible con-
ditional gene ablation while controlling for genetic
background and tamoxifen effects. Setdb1 ablated
ES cells exhibit severe growth inhibition, which is not
rescued by exogenous Nanog expression or cultur-
ing in naive pluripotency ‘2i’ media, suggesting that
the self-renewal defect is mediated through pluripo-
tency network independent pathways. Our strategy
to generate null mutant mouse ES cells is applicable
to thousands of genes and repurposes existing IKMC
Intermediate Vectors.
INTRODUCTION
Pluripotent stem cells have attracted much attention due to
their relevance for regenerative medicine (1). Mouse embry-
onic stem (ES) cells are pluripotent cells derived from the
inner cell mass of blastocyst stage embryos that typically re-
tain their normal diploid karyotype, are able to contribute
to all embryonic lineages including germ cells and provide a
faithful in vitro model of pre-implantation embryonic cells
(2). Mouse ES cells are highly amenable to genetic manipu-
lation (3), can be grown in sufficient numbers for conduct-
ing genome-wide assays and can be directed to differentiate
into a wide variety of more mature cell types. Many aspects
of gene function can be readily studied in ES cells or their
cultured derivatives, without the need for costly and time-
consuming generation and maintenance of mutant mouse
models. Thus, ES cells provide an excellent model system
for the elucidation of pathways required for cellular, devel-
opmental and disease processes.
A number of approaches have been used to achieve gene
depletion or ablation inmouseES cells. These include chem-
ical (e.g. ENU) and transposon-mediatedmutagenesis (4,5),
RNA inactivation (RNAi) (6), gene trapping (7,8), gene tar-
geting (4,9), targeted trapping (10,11), Zinc-Finger Nucle-
ases (ZFN) and transcription activator-like effector nucle-
ases (TALENs) (12) and CRISPR-Cas9 endonuclease sys-
tems (13,14). In functional genetic studies, residual gene
activity often occurs when using RNAi gene knockdown
techniques, which can mask a discernable phenotype. Ac-
cordingly, it is advantageous to inactivate both alleles of the
gene of interest in ES cells to facilitate detection of a phe-
notype. One approach is to produce a library of random in-
sertional mutations in Bloom-deficient ES cells (15) and se-
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lect for populations of homozygous mutant cells following
mitotic recombination (16,17). Insertional mutagenesis has
also been applied in haploid mouse ES cells (18,19), obvi-
ating the need to select for bi-allelic null mutational events.
Such libraries are ideal for forward genetic screens where
there is a strong selectable phenotype (e.g. resistance to a
drug or toxin, gain of ES self-renewal in differentiation-
permissive culture); however, genome coverage is limited
by the random nature of the insertional mutagenesis strat-
egy. Recently, the first individually cloned CRISPR-Cas9
genome-wide arrayed sgRNA library for the mouse was
described (20) which should facilitate candidate gene val-
idation upon its application to forward genetic screens in
mouse ES cells.
Bi-allelic mutations for complete gene inactivation at a
desired locus (i.e. reverse genetics) can be generated in a va-
riety of ways in mouse ES cells. In recent years, genome-
editing techniques have emerged which utilize site-specific
or RNA-guided nucleases capable of inducing null muta-
tions in specific genes and which can generate bi-allelic con-
stitutive null ES cells. In applications of ZFN and TALENs,
protein engineering of the site-specific nucleases is required,
validation of which can be time consuming (12). In apply-
ing the CRISPR-Cas9 endonuclease system, the intial step
to design and synthesize a guideRNA ismore tractable (12–
14,21). However there is concern about off-target effects
and themethodology for analyzing and reporting CRISPR-
Cas9 off-target activity remains to be standardized (3,22–
24). Schick et al. (25) reported that the incidence of ran-
dom genomic insertions of CRISPR-Cas9-based vectors
was 13-fold higher than that obtained when using conven-
tional gene targeting approaches, which are typically low, on
the order of 2%. While CRISPR-Cas9 nuclease technology
continues to develop and improve, arguably a reliable and
extensively validated method to generate null mutations in
mouse ES cells remains gene targeting using homologous
recombination. Some targeted loci are amenable to direct
selection of loss of heterozygosity events in alleles contain-
ing the neomycin selection cassette by treatment with high
concentrations of G418, thereby generating homozygous
mutant ES cells (26); however success using this approach
is unpredictable. Targeting both alleles of a gene to gener-
ate bi-allelic null ES cells can be achieved by recycling the
vector used for initial targeting of the first allele (27,28) or
by using two vectors with different selectable markers (29).
Recycling the vector is often inefficient due to preferential
retargeting of the first allele because of its’ greater homol-
ogy to the vector. We describe a novel strategy to generate
bi-allelic null ES cells utilizing the two vector approach, by
taking advantage of the extensive vector reagent andmutant
mouse ES cell line resources of the International Knockout
Mouse Consortium (IKMC) and InternationalMouse Phe-
notyping Consortium (IMPC) (30–33) and designing a new
vector for highly efficient ‘targeted trapping’ of the second
allele.
The IKMC undertook projects to systematically knock-
out all protein-coding genes in the mouse genome using
methods of high-throughput recombineering and gene tar-
geting by homologous recombination (34–36). That work
is complete, with targeted heterozygous knockouts avail-
able through IMPC public resources for >18 500 genes in
C57BL/6 ES cells (25,31,37) and ∼5000 strains of mutant
mice generated which have uncovered novel phenotypes of
known and previously uncharacterized genes (37–41). This
platform represents a valuable cost-effective resource for the
biomedical research community. A major fraction of the
IKMC resource, comprising the EUCOMM and KOMP-
CSD projects (31,35), was based on the use of a promoter-
less or promoter-driven targeting vector to generate the
‘knockout-first, conditional-ready’ tm1a allele (42). These
alleles were designed to initially disrupt gene function by
splicing to a lacZ gene trapping element, and can be modi-
fied through the action of Flp or Cre recombinases to gen-
erate conditional and deletion alleles (28). En route to con-
structing the final targeting vector, Gateway-adapted Inter-
mediate Vectors were produced by recombineering and cus-
tomGateway-adapted targeting elements (positive and neg-
ative selection cassettes) were incorporated into the Inter-
mediate Vector in an in vitroGateway exchange reaction to
produce the final targeting vector (35). These Intermediate
Vectors were purposely built in a modular way to enable the
construction of other useful alleles in ES cells, to extend the
utility of the resource (37,43).
In this study, we took advantage of the flexibility of the
EUCOMM and KOMP-CSD vector systems to design new
conversion cassettes, which we used together with the ex-
tensive library of EUCOMM and KOMP-CSD Intermedi-
ate Vectors, to rapidly assemble new insertion vectors for
‘targeted trapping’ (10) of the second allele, using the Gate-
way cloning system.We developed a highly efficient method
for generation of null mutant mouse ES cells, using exist-
ing IKMC resource ‘knockout-first conditional-ready’ het-
erozygous mutant ES cells and constitutively inactivating
the second allele with our new insertion-type targeted trap-
ping vectors built using the modular IKMC resource Inter-
mediate Vectors. To demonstrate the utility of our gene ab-
lation approach in mouse ES cells, we applied the method
to 14 genes with chromatin binding and/or epigenetic regu-
latory function, performing second allele targeting in cell
lines that already contain one corresponding ‘knockout-
first’ null allele made through promoterless vector target-
ing in the IKMC pipeline. A useful feature of our design
strategy is the ability to reinstate gene expression in our bi-
allelically targeted ES cells by reverting one mutant allele
with Flp recombinase, a powerful way to demonstrate phe-
notype specificity via restored molecular function. We illus-
trate these features in detail using two genes encoding epi-
genetic factors as examples: Cbx1 and Jarid2.
Notably, we designed our bi-allelic targeting strategy such
that integration events of the second vector re-targeting the
first allele are selected against early in the cell culture pro-
cess, and hence the inability to obtain clones during screen-
ing likely indicates the gene is essential in ES cells. Inter-
estingly, we failed to recover bi-allelic targeted clones for
three genes in our targeting experiments, including the hi-
stone methyltransferase encoding Setdb1 (also known as
Eset/Kmt1e). As an additional demonstration of the flex-
ibility and application of our method, we used an inducible
conditional strategy (28) with the same IKMC vectors and
cell lines but employing them in a different vector target-
ing order, combined with our novel insertion-type targeted
trapping vector, to inducibly ablate Setdb1 in ES cells. These
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experiments demonstrate that Setdb1 is indeed an essen-
tial gene in undifferentiated mouse ES cells. We explore the
functional consequences of inducible Setdb1 depletion, ob-
serving severely reduced growth and increased differentia-
tion of ES cells, leading us to investigate whether forced
reinstatement of naı¨ve pluripotency could rescue these ef-
fects. In summary, we describe several applications of our
bi-allelic gene targeting strategies for complete gene abla-
tion in mouse ES cells using our novel insertion-type tar-
geted trapping vectors, built upon the modular and flexible
IKMC public resource. Taken together, these flexible tools
offer biomedical researchers an opportunity to investigate
gene function in mouse ES cells using a gene knockout ap-
proach that is highly efficient and requires no vector design
work.
MATERIALS AND METHODS
Preparation of vector components
Details on EUCOMM and KOMP-CSD Intermediate Vec-
tor designs (35) obtained from public IKMC resources,
primers, and reading frames for pI hygGFP insertion vec-
tor construction used in this study are listed in Supple-
mentary Tables S1, S3 and S4. Additional information
on IKMC reagents can be obtained from the IMPC web
portal (33) (https://www.mousephenotype.org). DH10BEs-
cherichia coli containing individual Intermediate Vectors
were obtained from the IKMC (35) and individual clones
were expanded in liquid culture containing 10 g/ml
zeomycin and 50 g/ml ampicillin. Intermediate Vector
DNAwas digested with AsiSI to assess quality and confirm
the expected size of∼15 kb. The pL1L2 RloxP plasmid was
grown in DH5alpha E. coli with 20 g/ml clonNAT. The
pL3L4 hygGFP plasmids were grown in DB3.1 E. coli with
15 g/ml kanamycin and 12.5 g/ml chloramphenicol. All
DNA for cloning was prepared using Qiagen plasmid midi
kits.
Generation of pI hygGFP plasmids
Three-way Gateway (Invitrogen™) reactions were per-
formed in individual microcentrifuge tubes using LR
Clonase II Plus enzyme mix (Invitrogen) according to the
manufacturer’s instructions. The following vector compo-
nents were reacted in equimolar amounts overnight at 25◦C:
200 ng Intermediate Vector, 40 ng pL1L2 RloxP plasmid
and 100 ng pL3L4 hygGFP plasmid of the appropriate
reading frame. After inactivation with Proteinase K, the re-
actions were brought to 20 l volume with HPLC-grade
water, were microdialyzed on 0.1 m filter (VCWP Milli-
pore) over HPLC-grade water for 1.5 h and the resulting
liquid collected into a fresh tube and brought back up to
20 l with HPLC-grade water. The dialyzed Gateway re-
action was transformed into electrocompetant DH10B E.
coli containing the pSC101 705Cre temperature inducible
chloramphenicol resistant Cre-expressing plasmid (Gene
Bridges), which had been induced as follows: the DH10B
+ pSC101 705Cre E. coli were cultured in LB broth with
17.5 g/ml chloramphenicol for 24–30 h (to saturation)
at the non-permissive temperature of 30◦C. A total of 400
l of the saturated culture was then used to seed a 20 ml
short-term culture in LB broth with 17.5 g/ml chloram-
phenicol at 30◦C until the OD600 reached 0.4. Then the
short-term culture was induced at 42◦C for 30 min (to ex-
press Cre recombinase), with constant shaking, followed
by cooling of the cells on ice. Cells were made electrocom-
petant by three fast washes in HPLC-grade water (cells
were spun at 4000 rpm for 5 min at 4◦C each time). All
following steps were performed quickly and components
were kept on ice. Following the final wash the E. coli cells
were gently resuspended in 500 l ice-chilled HPLC-grade
water. For each transformation, 50 l of the electrocom-
petant cells were gently mixed with 2 l of the Gateway re-
action, transferred to a pre-cooled electroporation cuvette
(0.1 cm gap, BioRad GenePulser) and electroporated us-
ing EC1 setting (BioRad MicroPulser). For recovery cul-
ture, 500 l of 37◦C Super Optimal broth with Catabolite
repression (SOC) media (ThermoFisher) was added per cu-
vette, mixed and transferred to a 14 ml conical tube and
incubated with shaking for 1 h at 37◦C. Up to 250 l of
the recovery culture was plated onto YEG agar plates con-
taining 25 g/ml kanamycin and 50 g/ml streptomycin.
Note that DH10B clones with the proper final targeting
insertion vector (containing the gapped region) will only
grow on YEG/kan/strep if the loxP-flanked ‘critical exon’
has been deleted by Cre activity, as loss of rpsL reverts
DH10B to being streptomycin resistant. LR Clonase neg-
ative reactions can be used to assess background. Clones
obtained from LR Clonase negative reactions that grow on
YEG/kan/strep should contain the pL3L4 hygGFP back-
bone vector; the level of background will help determine the
number of +LR Clonase colonies necessary to pick to ob-
tain a clone with the proper final targeting insertion vector.
We routinely picked 12 clones from each +LRClonase reac-
tion and performed Sanger sequencing analysis on Qiagen
miniprepped DNAwith primers LR (to confirm deletion of
the critical exon region) and hygro 1R (to confirm the read-
ing frame), on all clones followed by restriction enzyme di-
gests (AsiSI cuts twice; PmeI should linearize) to confirm
each vector.
Final insertion targeting vector (pI hygGFP) DNA was
prepared using a Qiagen plasmid midiprep or maxiprep
kit and were linearized with PmeI before proceeding to ES
cell electroporation. All other vector DNA used for ES cell
electroporation was prepared using Qiagen plasmid maxi
kits. pI hygGFP vectors that contain additional PmeI site(s)
within the genomic homology arms cannot be linearized in-
tact and so should be eliminated from the potential vec-
tor construction pool. To classify vectors, we used bulk
data underlying the iMITS component of the IMPC web-
site (33) (https://www.mousephenotype.org/imits/targ rep/
alleles). We counted numbers of vector designs and corre-
sponding gene loci represented within the promoterless and
promoter-containing IKMC targeting vectors and analyzed
their IntermediateVector designs.Using genomic sequences
of the 5′- and 3′-homology arms of the vector designs
as extracted from GRCm38 genomic sequences, we classi-
fied vectors into those with or without extra PmeI sites(s)
(GTTT/AAAC) (Supplementary Table S2a) and noted de-
tails of those genes represented by promoterless type IKMC
vector designs (Supplementary Table S2b).
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Cell culture
All ES cells used in this study are murine. Wild type (WT)
JM8 ES cells (44) and all JM8-based ES cell lines used
or derived in this study, were cultured as described in
IKMC protocols (35), without fibroblast feeders on tis-
sue culture plates coated with 0.1% gelatin (Sigma) in
phosphate-buffered saline (PBS), unless stated otherwise.
ES cells were routinely cultured in ‘regular ES cell media’
(serum+LIF) containing Knockout DMEM (Gibco) sup-
plemented with 10% fetal bovine serum (Invitrogen; pre-
screened for supporting undifferentiated ES cell culture),
2 mM L-Glutamine (Gibco), 0.05 mM -mercaptoethanol
(Sigma or Gibco) and LIF (Chemicon/Millipore) accord-
ing to manufacturer’s instructions. For experiments with
cell lines once established and expanded, we added 1×
penicillin–streptomycin (Gibco). For ES cell culture under
‘2-inhibitor’ (2i) conditions, we used a mixture of 75% 2i
culture media (2,45) plus 25% ‘regular ES cell media’, all
supplemented with LIF (Chemicon/Millipore) according
to manufacturer’s instructions. Cells were plated onto tis-
sue culture plastic previously coated in laminin (10 g/ml
in PBS; Sigma) for aminimumof 4 h in a 37◦C tissue culture
incubator followed by coating in 0.1% gelatin in PBS for at
least 5 min at room temperature. The 2i culture media was a
1:1mixture ofNeurobasal andDMEM:F12media (Gibco),
to which was added 0.5× N-2 Supplement (Gibco), 0.5×
B-27 Supplement (Gibco), 2 mM L-Glutamine, 0.1 mM
-mercaptoethanol, 1 M PD032590 (Stemgent), 3 M
CHIR99021 (Stemgent) and 1× penicillin–streptomycin
(Gibco). Cells weremaintained in 75% 2i culturemedia plus
25% ‘regular ES cell media’ for several passages prior to use
in experiments.
Electroporation and ES cell line generation
To generate the doubly targeted tm1a/tm2 mutant ES cells
or the singly targeted tm2/+ control lines, the tm1a/+ orWT
JM8 ES cells respectively, were electroporated with the rel-
evant linearized pI hygGFP vector using a 25-well cuvette
electroporation system as described (35). Cell suspensions
of ∼1 × 107 cells in PBS and 2 g of linearized vector were
mixed immediately prior in a final volume of 120 l, elec-
troporated then allowed to rest for 20 min, then recovered
into 20 ml of ES cell media without selective agents and
plated onto 10 cm dishes. The following day selection us-
ing 120 g/ml hygromycin B (Calbiochem) in media was
started and continued until colonies were picked 10–14 days
later, with daily media changes. Routinely, 24 colonies per
electroporation were picked into 96-well plates and for sub-
sequent culturing the concentration of hygromycin B was
reduced to 100 g/ml. Cells were split into replicate 96-well
plates for archiving and preparation of genomic DNA for
genotyping as described (35).
To revert the mutant tm1a allele to the pre-conditional
tm1c allele, the recombinase flippase (Flp) was transiently
transfected into ES cells by introducing a Flp encoding
puromycin resistant plasmid (pCAGGs-FLPe) (46). A total
of 50 g of circular plasmid was combined with approxi-
mately 5 × 107 ES cells in PBS in a final volume of 700 l
and electroporated in a 0.4 cm gap cuvette in a GenePulser
electroporator (BioRad) at 250 V and 500 F on high ca-
pacitance setting. Cells were allowed to rest for 20 min fol-
lowing electroporation and then the mixture was recovered
into 20 ml of media without selective agents and equal vol-
umes were plated onto two 10 cm dishes. Selection in 0.8
g/ml puromycin (Sigma) was started 36–48 h after elec-
troporation and was maintained for 3 days after which cul-
ture continued without any selective agents, with daily me-
dia changes throughout, until colonies became visible. A
duplicate 10 cm colony plate was stained with X-gal in or-
der to quantify the number of blue versus white colonies
to determine an adequate number of colonies to pick for
screening/genotyping, to increase efficiency. Blue stained
cells indicate presence of the intact tm1a allele due to the
expression of the -galactosidase encoding lacZ transgene
in the lacZ-neomycin phosphotransferase (-geo) trapping
cassette, as shown in Supplementary Figure S2e, whereas
absence of blue stain in Flp recombinase treated cells likely
indicates a desired reversion event whereby the betageo cas-
sette located between two flippase recognition target (FRT)
sites is excised by Flp recombinase, generating the tm1c
allele. Colonies were picked into 96-well plates, expanded
and replicated for further X-gal staining to identify un-
stained (white) clones, archiving and preparation of ge-
nomic DNA for genotyping. Expanded revertant clones of
confirmed genotype were tested for puromycin sensitivity
as subsequent genetic manipulations might involve the use
of puromycin selection. We note however, that if a differ-
ent targeted gene of interest is expressed at a low level, the
initial X-gal stain visual screening method to detect a tm1c
reverted allele may not be sensitive enough, in which case
only the genomic DNA-based screening methods for geno-
typing the reversion event could be applied.
To generate theSetdb1 inducible conditional ES cell lines,
heterozygous ES cell lines with one WT and one tm1a al-
lele were first transiently transfected with the pCAGGs-
FLPe vector to generate tm1c /+ revertant lines, as de-
scribed above. These revertant lines were then transfected
with the pI hygGFP vector to generate tm1c/tm2 doubly
targeted ES cell lines. The final step utilized the Rosa26-
CreERT2 knock-in plasmid to target a drug inducible mu-
tant estrogen receptor Cre fusion protein into the ubiqui-
tously expressed Rosa26 locus (47,48). The tm1c/tm2 (or
tm1c/+ as controls) ES cell lines were targeted with 2 g
of SfiI-linearized Rosa26-CreERT2 plasmid by electropora-
tion in the 25-well cuvette as described above except that 5
× 106 cells were used per electroporation. Cells were plated
onto two 10 cm dishes at densities of 1 × 106 or 5 × 105 per
plate and selection in 1 g/ml puromycin was started 48 h
after plating and continued until colonies were picked 10–12
days later, with daily media changes. Colonies were picked
into 96-well plates for screening and polymerase chain re-
action (PCR)-based genotyping. Expanded Setdb1 tm1c/+
and tm1c/tm2 ES clonal cell lines containing the Rosa26-
CreERT2 cassette were treated for a defined period (48
h unless otherwise noted) with 0.8 M hydroxytamoxifen
(4′OHT, Sigma) to induce Cre activity and convert the tm1c
allele to tm1d and then were subsequently cultured without
4′OHT for use in downstream assays. Concurrently, tm1c/+
ES clonal cell lines withRosa26-CreERT2were cultured un-
der identical conditions in 4′OHT, as controls due to possi-
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ble effects of toxicity upon exposure to 4′OHT and/or Cre
activity (49). We note that there is a variable but low level of
recombination at the Setdb1 locus occurring in the absence
of Cre induction in some samples (e.g. refer to Supplemen-
tary Figure S7a and c). Such ‘leakiness’ is not uncommon
with inducible systems and the CreERT2 cassette has com-
pared favorably to other Cre induction cassettes in specific
tests to quantify the extent and functional impact of back-
ground recombination in vivo in mice (47).
To generate ES cell lines constitutively expressingNanog,
we electroporated 30 g of ScaI-linearized pPyCAG-
Nanog-IRES-Blasticidin transgenic vector (gift from Jose
Silva, University of Cambridge) into 5× 107 ES cells, using
a GenePulser electroporator (BioRad) set at 800 V and 3
F, in a final volume of 800 l PBS in a 0.4 cm gap cuvette.
Cells were plated on 10 cm gelatinized plates and selection
in 6g/ml blasticidin (ThermoFisher) was started 48 h later
and continued thereafter. Colonies were picked 9 days later
into 96-well plates to establish stable cell lines and Nanog
expression in a subset of four clones following expansion
was confirmed by quantitative real time-polymerase chain
reaction (qRT-PCR) analysis.
Genomic DNA preparation and PCR genotyping
For screening ES cell clones, genomic DNA was prepared
from 96 well plates as described (35). To confirm the
genotype of expanded ES cell clones, genomic DNA was
prepared from confluent cultures of 24 well plates using
DNAzol (Invitrogen). Genotyping by long range PCR was
done using either the Expand Long Template PCR System
(Roche) with System 2 Buffer plus an extra 1.25 mMMgCl2
and the additives 1% DMSO and 67 mM Trehalose, or the
SequalPrep Long PCR kit with dNTPs (Invitrogen), ac-
cording tomanufacturer’s instructions and the following cy-
cling protocol was performed in 96 well format and heated
lid: 94◦C 3 min; 10 cycles of: 94◦C 10–15 s, 70◦C 30 s with
−1◦C per cycle, 68◦C 6–7 min; 25 cycles of: 94◦C 10–15 s,
60◦C 30 s, 68◦C 6 min plus add 20 s per cycle; 1 cycle: 7 min
at 68◦C (Roche Expand polymerase) or 72◦C (SequalPrep
polymerase); 4◦C hold. Short range PCRs were done using
PlatinumTaq polymerase (Invitrogen)with themanufactur-
ers recommended conditions. PCRs were done in BioRad
Tetrad or Genomic Research Instrumentation Ltd (GRI)
G-Storm thermocyclers.
Genotyping strategies and PCR primers
The recombineering oligonucleotide primers from the
IKMC gene targeting pipeline (35) used to generate the In-
termediate Vectors which were used in this study are listed
in Supplementary Table S4; the 5′ and 3′ ends of the ge-
nomic homology arms in each vector are denoted by the
G5 and G3 primers respectively, whereas the U3 and D5
primers respectively denote the 5′ and 3′ boundaries of the
loxP flanked region within the 3′ genomic homology arm.
This information is included as it is critical for the geno-
typing strategy of targeted cells to identify genomic DNA
sequence external to that which is contained in the target-
ing vectors, as one primer for PCR screening needs to be
externally located.
Long-range PCR (LR-PCR) (35) was used to screen
for targeted cells resulting from electroporations of the
pI hygGFP vectors into either heterozygous IKMCmutant
cells (tm1a/+) or into WT cells as a control and genotypes
of expanded clones were confirmed with the same primer
sets, listed in Supplementary Table S3, prior to use in fur-
ther experiments. We confirmed the presence of the ‘knock-
out first’ allele (tm1a) using a gene-specific forward primer
external to the 5′ genomic homology arm (gf3) and a vector-
specific reverse primer within the lacZ cassette (LAR 3). To
detect targeting of the second allele (tm2) with pI hygGFP
vector, we used a gene-specific forward primer, ex5, that
bindswithin the deleted genomic sequence regionwithin the
pI hygGFP targeting vector (this region would undergo gap
repair and therefore be present only in the targeted allele
in the genome) and a vector-specific reverse primer in the
hygromycin-GFP cassette, hygro 1R, as illustrated in Fig-
ure 1B and Supplementary Figure S2a. The size range of
these LR-PCR products is 6–7 kb, as shown in Supplemen-
tary Figure S2b and c. Random insertions of the targeting
vector are not detected with this primer combination.
ES cell clones obtained following transient Flp expres-
sion (which should convert the tm1a allele to the tm1c allele)
were initially screened for loss of X-gal staining resulting
from deletion of the FRT flanked lacZ-neomycin cassette
and those clones negative for staining were genotyped by
LR-PCR on genomic DNA using a locus specific external
forward primer 5′ to the 5′ genomic homology arm of the
vector, gf3 and a vector specific reverse primer, LR, which
binds just 3′ to the 3′ loxP site of the tm1a and tm1c alle-
les, as shown in Figure 1D and Supplementary Figure S2a.
These primers amplify the tm1a allele with an expected am-
plicon size of approximately 12 kb, whereas the amplicon
size for the tm1c allele template with recombined FRT sites
will be reduced to ∼7 kb, as shown in Supplementary Fig-
ures S2d and 5a left panel). No amplification occurs from
the tm2 allele since the LR reverse primer does not bind this
template.
Revertant (tm1c/+) ES cell clones following targeting
with the pI hygGFP insertion vector (as we have demon-
strated for Setdb1) were genotyped for targeting as de-
scribed above, however, this assay will not distinguish be-
tween cis and trans targeting of the conditional (tm1c) al-
lele. To detect undesirable cis targeting events, clones were
further screened by LR-PCR using vector-specific primers,
R1 amp F2 and hygro 1R, which bind to the tm1c allelic
and hygromycin gene sequences (contained in pI hygGFP
vector) respectively. This primer set will amplify a 6 kb frag-
ment if the two integrated vectors are in cis; no product
would result if they are in trans configuration, as shown in
Supplementary Figure S5a middle panel.
For genotyping of Rosa26-CreERT2 knockin vector
targeted ES cells, we inferred correct integration based
upon successful functioning of the CreERT2 cassette upon
4′OHT induction, by the ability of Cre to recombine the
loxP sites at the Setdb1 tm1c locus. This was done using
short range PCR at the tm1c allele whereby clones with a
functional integrated CreERT2 cassette would show a re-
duced amplicon size after exposure to Cre activity, turning
the tm1c allele into tm1d, as shown in Supplementary Fig-
ure S5a right panel. Southern-blot and PCR-based geno-
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typing strategies for Rosa26-CreERT2 vector targeting have
been described, for use in further validation (47,48).
Each PCR described in this section was done in a sepa-
rate reaction with one primer pair. All primer sequences are
listed in Supplementary Table S3.
Descriptions of cell-based assays and microscopy, west-
ern blot analysis, gene expression analysis, ChIP, sequenc-
ing and ChIP-seq analyses and associated references are
available in the Supplementary Materials and Methods.
RESULTS
Construction of insertion vectors for second allele targeting
Taking advantage of themodular design of IKMC targeting
vectors (35), we re-configured Intermediate Vectors from
the resource (Supplementary Table S1 and Figure S1a) into
insertion-type vectors (4) for high efficiency ‘targeted trap-
ping’ (10) of the second allele, applicable to expressed genes
in mouse ES cells (Supplementary Figure S1). To this end
we developed: (i) an adaptor module (pL1L2 RloxP; Sup-
plementary Figure S1b) for the introduction of a rare PmeI
restriction site for linearization and one loxP recombina-
tion site upstream of the ‘critical exon’ (35) and (ii) a series
of hygromycin-GFP gene trap cassettes (pL3L4 hygGFP;
Supplementary Figure S1c) in three reading frames, to re-
place the plasmid backbone. The reading frame is deter-
mined by the end phase of the most 3′ exon within the ge-
nomic homology region. Expression of the hygromycin re-
sistance gene and GFP reporter is dependent on splicing
to the endogenous gene to produce an in-frame fusion pro-
tein and ribosome-skipping elements (‘2A-like’ sequences)
(35,50) were included in order to express multiple proteins
from the same open reading frame and ensure optimal co-
expression of the transgenes. Constructs are assembled in a
three-part Gateway™ exchange reaction with the Intermedi-
ate Vector, the pL1L2 module and the pL3L4 trapping cas-
sette (Supplementary Figure S1d) The final insertion-type
targeted trapping vector pI hygGFP is recovered by trans-
formation into bacteria expressing Cre recombinase which
deletes the floxed ‘critical exon’ (35) in the vector and cre-
ates a gap in the genomic homology (Supplementary Figure
S1d). This gap facilitates the use of PCR-based genotyping
to specifically screen for the targeted mutant allele, since a
primer annealing site within the deleted region will be re-
generated only upon gap repair at the locus in ES cells fol-
lowing homologous recombination (51) and clones in which
random integration of the vector occurred will be PCR-
negative.
Generation and validation of epigenetic regulator bi-allelic
mutant ES cell lines
Insertion-type targeted trapping pI hygGFP vectors were
electroporated into the corresponding heterozygous IKMC
‘knockout first’ tm1a/+ ES cells with the aim of generating
bi-allelic null mutants (Figure 1A). The insertion targeting
vectors pI hygGFP are prepared by linearization with PmeI
restriction enzyme and electroporated into IKMC targeted
heterozygous ES cells that contain the ‘knockout-first’ al-
lele (tm1a) (35) (Figure 1A). The presence of an additional
PmeI restriction site within the IKMC Intermediate Vec-
tor genomic homology arms would preclude its’ use as a
pI hygGFP targeting vector in our system and this should
be checked prior to final vector construction. Our analysis
of IKMC Intermediate Vectors showed that 11.5% of vec-
tors based on the IKMC ‘knockout-first’ promoterless cas-
sette design, are not suitable for this reason (Supplemen-
tary Table S2a). Our bi-allelic ‘targeted trapping’ method
was designed for application to genes expressed in mouse
ES cells. Our strategy is therefore applicable to all genes
represented with a KOMP-CSD or EUCOMM ‘knockout-
first’ tm1a allele from a promoterless targeting vector, since
that class of vectors specifically targets expressed genes (35).
This set of 2257 promoterless vector designs for tm1a al-
lele generation represents 1377 and 837 genes from the
KOMP-CSD and EUCOMM pipelines respectively, noting
that some genes have more than one vector design associ-
ated with them (Supplementary Table S2b) (31,33).
Following homologous recombination with the WT al-
lele, the entire pI hygGFP vector is integrated into the
genome in a single crossover event, placing the hygromycin-
GFP cassette downstream of the genomic homology region
in the vector and duplicating genomic sequences contained
in the vector, thereby generating the second mutant allele
(tm2) (Figure 1B). Conversely, homologous recombination
in cis into the ‘knockout-first’ allele (tm1a) is not expected
to give rise to hygromycin-resistant clones, as downstream
gene expression in the locus is blocked by the upstream pro-
moterless lacZ-neomycin trapping cassette. Hence, only bi-
allelic targeted events are recovered from experiments in-
troducing the final PmeI-linearized pI hygGFP vector into
IKMC heterozygous mutant cell lines containing the tm1a
allele at the same locus, making the entire process highly
efficient. Moreover, absence of bi-allelic targeted clones in-
dicates the gene is likely essential for normal ES cell growth.
LR-PCR (35) was used to screen typically 24 ES cell
clones per gene (Table 1; Supplementary Figure S2a–c; Sup-
plementary Tables S3 and S4). We recovered doubly tar-
geted ES cell clones (tm1a/tm2) for 11 of the 14 epigenetic
regulatory genes we attempted to mutate, with an average
targeting efficiency of 60%, ranging from 17–100% (Table
1). For clarity, we refer to the pI hygGFP targeted mutant
allele as ‘tm2’ to denote the second targeted mutation (Fig-
ure 1B), however the official Mouse Genome Informatics
(MGI) allele names for each gene mutation follow stan-
dard nomenclature guidelines and are listed in Table 1. In
parallel, WT ES cells were electroporated with pI hygGFP
vectors as a positive control for 9 of our 14 loci, and for
this set we achieved an average targeting efficiency of 80%,
with a range from 50–100% (Table 1). Doubly targeted ES
lines were not recovered for three genes: Ddx27, Phf20 and
Setdb1, despite the fact that we could readily target these
genes in WT ES cells with the corresponding pI hygGFP
vector to obtain heterozygous cell lines, validating our vec-
tors and indicating that these genes are essential for ES cells.
We observed a lower bi-allelic targeting efficiency in Smyd5
heterozygous mutant cells (25%) than in WT cells (62.5%),
suggesting decreased cell viability of null ES cells. We also
observed a low targeting efficiency for the Suv420h1 (also
known as Kmt5b) gene (17%), however in this case we did
not target WT ES cells for comparison.
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Figure 1. Schematic of allele structures in second allele targeted and revertant ES cells and cell line validation. (A) Insertion-type targeting vector
pI hygGFP for inactivation of the WT allele in ES cells heterozygous for a standard IKMC knockout-first allele (tm1a). (B) Structure of the bi-allelic locus
after targeting the second allele. The tm2 allele contains the pI hygGFP targeting cassette and duplicated homology region, where exon 2 is re-generated by
gap repair. (C)Western blots of Cbx1 and Jarid2 parental IKMCheterozygous ES cells (B01 and E08 lines), and examples of cell lines following pI hygGFP
electroporation including doubly targeted ES cells (1a/2) showing the absence of protein expression, and failed targeting events (1a/+). (D) Reversion from
null mutant (1a/2) to conditional mutant (1c/2) by Flp recombinase. (E) Western blots of mutant (1a/2) and reverted (1c/2) Cbx1 and Jarid2 ES cell lines
showing re-expression of protein. Primers for LR-PCR genotyping are indicated by small arrows and -tubulin was used forWestern blot loading controls.
(F) Rescue of Polycomb PRC1 recruitment to PRC2 target genes in Jarid2 revertant cell lines (1c/2), shown by reinstatement of Mel18 binding at known
Jarid2-dependent gene promoter regions, assessed by chromatin immunoprecipitation (ChIP)-qRT-PCR.Hprt is a control locus known to be negative for
PRC1 binding. Results show mean ± s.d. of three biological replicates (independent cell lines), where values are expressed as relative fold-enrichment over
10% input chromatin. Asterisks indicate statistically significant differences between Jarid2 revertant (1c/2) and null (1a/2) cell lines (P < 0.05, one-tailed
Student’s t-test).
We chose two doubly targeted viable cell lines, Jarid2 and
Cbx1, for further validation and as an example of the flex-
ibility of our approach (Figure 1 and Supplementary Fig-
ure S2). Western blots confirmed the absence of full length
protein in each line (Figure 1C and Supplementary Figure
S2d). As we employed a targeted trapping (10) strategy, fu-
sion transcripts will be generated from each mutant allele
which are predicted to lead to the expression of truncation
products, which are often unstable. The Cbx1 tm2 allele is
predicted to form a 172 aa (20 kDa) truncated protein re-
sulting from splicing of exons 1–4 to the splice acceptor site
of the vector, while the Jarid2 tm2 allele is expected to give
rise to a truncated protein of 97 aa (11 kDa) encoded by ex-
ons 1 and 2. Truncated products forCbx1 and Jarid2 doubly
targeted loci were not detected in western blotting with anti-
bodies that would recognize the predicted truncation prod-
ucts, indicating that these truncated products are unstable
and the mutant ES cells are indeed null. We did not observe
any overt phenotypes ofCbx1 or Jarid2 null mutant ES cells
during routine culturing.
Reversion of Jarid2 and Cbx1 mutant ES cells
To confirm causality in a loss-of-function model, it is nec-
essary to re-introduce WT protein and rescue the pheno-
type. We genetically reverted the null ‘knockout-first’ al-
lele (tm1a) to a conditional allele (tm1c) (35) which is de-
signed to express full-length protein, by excising the lacZ-
neomycin trapping cassette with Flp recombinase through
transient transfection of the pCAGGs-FLPe vector (46),
leaving a single FRT site and two loxP sites flanking the
‘critical exon’ (Figure 1D and Supplementary Figure S2a).
ES cells containing the tm1a allele stain blue when ex-
posed to X-gal due to the presence of the lacZ gene in
the trapping cassette (Supplementary Figure S2e). Follow-
ing a ‘blue/white’ pre-screen for X-gal staining to isolate
negative ES cell clones that have lost the lacZ gene, clones
were genotyped by LR-PCR on genomic DNA to detect
the product size reduction resulting from excision of the
lacZ-neomycin cassette, indicating successful allelic rever-
sion of tm1a to tm1c (Supplementary Figure S2f). Allelic
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Table 1. Targeting frequencies following electroporation of insertion vectors pI hygGFP intoWT JM8 (parental or subcloned N4 or F6 lines as indicated)
and heterozygous mutant tm1a/+ (knockout first) ES cells, selection in hygromycin and screening/genotyping by long range-PCR on genomic DNA
Targeted
gene (MGI
symbol) ES cell line/allele used for targeting
ES cell clone
ID
Number of
colonies
screened
% clones
targeted
MGI name for
pI hygGFP targeted
allele (tm2)
Brd8 JM8.N4 24 96 Brd8tm1Wcs
JM8.N4/Brd8 tm1a(EUCOMM)Wtsi/+ E10 22 100
Cbx1 JM8.N4/Cbx1tm1a(EUCOMM)Wtsi/+ B01 24 45.8 Cbx1tm1Wcs
Ddx27 JM8.N4 24 100 Ddx27tm1Wcs
JM8.F6/Ddx27 tm1a(KOMP)Wtsi/+ E01 6* 0
Dot1l JM8 parental/Dot1l tm1a(KOMP)Wtsi/+ D02 24 54.2 Dot1ltm1Wcs
Epc2 JM8 parental/Epc2 tm1a(EUCOMM)Wtsi/+ B12 24 45.8 Epc2tm1Wcs
Ing3 JM8.N4 24 79 Ing3tm1Wcs
JM8.N4/Ing3 tm1a(EUCOMM)Wtsi/+ E07 16 81
Jarid2 JM8 parental/Jarid2 tm1a(KOMP)Wtsi/+ A08 24 62.5 Jarid2tm1Wcs
JM8 parental/Jarid2 tm1a(KOMP)Wtsi/+ E08 24 62.5
Kdm4c JM8.N4 12 100 Kdm4ctm1Wcs
JM8.F6/Kdm4c tm1a(KOMP)Wtsi/+ D03 24 75
Mier1 JM8.N4 24 66.7 Mier1tm1Wcs
JM8.N4/Mier1 tm1a(EUCOMM)Wtsi/+ A04 24 66.7
Phf20 JM8.N4 24 62.5 Phf20tm1Wcs
JM8.N4/Phf20 tm1a(EUCOMM)Wtsi/+ F07 0 0
Setdb1 JM8.N4 16 100 Setdb1tm1Wcs
JM8.N4/Setdb1 tm1a(EUCOMM)Wtsi/+ D08 40 0
Smyd5 JM8.N4 16 62.5 Smyd5tm1Wcs
JM8.N4/Smyd5 tm1a(EUCOMM)Wtsi/+ G01 24 25
Supv3l1 JM8.N4 24 50 Supv3l1tm1Wcs
JM8.N4/Supv3l1 tm1a(EUCOMM)Wtsi/+ B08 24 70.8
Kmt5b JM8 parental/Kmt5b tm1a(KOMP)Wtsi/+ C01 24 16.7 Kmt5btm1Wcs
*Only a low number of colonies were obtained; all were screened.
reversion at the Jarid2 and Cbx1 loci was confirmed by
Western blotting on genotyped clonal cell lines showing re-
stored protein expression (Figure 1E and Supplementary
Figure S2d). To elucidate possible downstream target genes
and pathways affected by gene ablation, we compared gene
expression profiles in Cbx1 and Jarid2 revertant cell lines
(tm1c/tm2) with corresponding null mutant ES cell lines
(tm1a/tm2). ForCbx1, only 20 genes showed altered expres-
sion (P < 0.05), with 8 genes upregulated and 14 downreg-
ulated in revertant compared to null cells (Supplementary
Table S5). In contrast, our comparison of gene expression in
Jarid2 null and revertant cells yielded 242 upregulated and
212 downregulated genes in revertant compared to null ES
cells (P < 0.05) (Supplementary Table S6). Gene Ontology
(GO) analysis of the genes upregulated upon Jarid2 rever-
sion identified an enrichment of categories relating to RNA
polymerase II transcription factor activity, the nucleosome
and cell differentiation and developmental pathways (P <
0.05; Supplementary Figure S3a). Analysis of published tar-
get gene datasets for factors involved in ES cell regulation
(SupplementaryMaterials andMethods) was performed on
the Jarid2 revertant versus null expression dataset and re-
vealed significant differences in expression of targets of the
Polycomb PRC2 component Suz12 and histone H3K27-
trimethyl marked genes and targets of the pluripotency
transcription factors Nanog, Sox2, Nac1, Dax1 and Cnot
(P < 0.01; Supplementary Figure S3b). Functional rever-
sion of a known Jarid2 phenotype at themolecular level was
demonstrated by showing restored binding of Mel18 (Poly-
comb PRC1 component) at known Polycomb PRC2 target
gene promoters (52) in Jarid2 revertant ES cells, whereas
absence of binding is observed as expected in Jarid2 null ES
cells, using ChIP coupled with qPCR (Figure 1F and Sup-
plementary Figure S4).
Generation and functional analysis of inducible conditional
Setdb1 mutant ES cell lines
We did not recover bi-allelic targeted ES cell clones for
Ddx27, Phf20 and Setdb1 (Table 1), even though our
pI hygGFP vectors for these genes efficiently target WT ES
cells. This suggested that these genes are required for ES cell
survival since our bi-allelic targeting system was designed
to select against re-targeting the ‘knockout-first’ (tm1a) al-
lele. To explore this further, we made use of the flexibil-
ity of our system and employed an inducible conditional
gene ablation strategy, involving three vector transfection
steps followed by drug induction, to verify that the his-
tone H3K9 methyltransferase Setdb1 is an essential gene
in ES cells (Figure 2 and Supplementary Figure S5). First,
the ‘knockout-first’ allele (tm1a) (35) of Setdb1 heterozy-
gous IKMC ES cells was converted to a conditional allele
(tm1c) with Flp recombinase (pCAGGs-FLPe vector). Sec-
ond, the WT allele was targeted with the pI hygGFP vector
to generate Setdb1 tm1c/tm2 ES cells. Third, inducible Cre
recombinase (Cre-ERT2 knock-in vector) was introduced
into the ubiquitously expressedRosa26 locus by gene target-
ing. Upon induction with 4′-hydroxytamoxifen (4′OHT),
Cre is activated, deleting the ‘critical exon’ in the tm1c allele
to generate null (tm1d/tm2) ES cells (Figure 2A). Following
the first and second allele modification steps, clones were
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Figure 2. Generation and functional analysis of inducible conditional Setdb1mutant ES cell lines. (A) Allelic structures and workflow of vector electropo-
rations. IKMC heterozygous ‘knockout-first’ (tm1a/+) ES cells are treated with Flp recombinase to generate a conditional allele (tm1c) and targeted with
pI hygGFP to generate conditional/null (tm1c/tm2) cells. Cre-ERT2 is then introduced by targeting vector knockin into theRosa26 locus. Upon treatment
with 4′OHT, Cre recombinase activity removes the floxed ‘criticial exon’ of the tm1c allele to generate bi-allelic null cells (tm1d/tm2). Primers for PCR
genotyping are noted as small arrows. (B) Western blots showing absence of full-length Setdb1 protein (black arrow) in the Setdb1 tm1d/tm2 mutant ES
cell lines after treatment with 4′OHT. A 39 kDa truncation product is generated from the tm2 allele (gray arrow). -tubulin was used as a loading control
(open arrow). (C) Setdb1 tm1d/tm2 mutant ES cells plated at low density (1 × 10∧3 cells per 10cm dish; following a 48 h 4′OHT treatment period) are
unable to form colonies of undifferentiated ES cells, whereas control Setdb1 +/tm1d heterozygous ES cells (4′OHT treated and plated concurrently) exhibit
normal undifferentiated ES cell colony morphology; a representative example is shown. Cells were stained with methylene blue 8 days after plating. (D)
Growth of 4′OHT treated Setdb1 tm1d/tm2 null ES cells is severely compromised, while 4′OHT treated control Setdb1 +/tm1d heterozygous ES cells retain
robust growth characteristics similar to non-treated Setdb1 tm1c/+ and tm1c/tm2 cells. Cells were plated following a 48 h 4′OHT treatment and counted
at the time intervals indicated. Data points are the mean of three biological replicates (independent cell lines), error bars indicate s.d. (E) 4′OHT-treated
Setdb1 tm1c/tm2 ES cells start to differentiate by 6 days after treatment and gradually lose alkaline phosphatase (AP) activity, while treated control Setdb1
+/tm1d ES cells retain AP activity and normal ES cell morphology.
genotyped by long-range genomic PCR, whereas after the
final step of Cre vector knock-in and induction, the clones
were genotyped by short-amplicon genomic PCR (Supple-
mentary Figure S5a). Inducible conditional Setdb1 tm1c/+
heterozygous cells were generated concurrently as a control
by collecting clones following the first step of Flp recombi-
nase treatment and then proceeding directly to knock-in the
Cre vector (Figure 2A and Supplementary Figure S5a). In
order to control for potential changes due to drug treatment
alone (49), for most experiments we compared ‘experimen-
tal’ tm1c/tm2 (becoming tm1d/tm2) with ‘control’ tm1c/+
(becoming tm1d/+) ES cells at timepoints before and after
concurrent 4′OHT treatment.
Following 48 h treatment of bi-allelic inducible condi-
tional mutant ES cell clones (tm1c/tm2) with 4′OHT, full-
length Setdb1 protein is absent in Setdb1 mutant (now
tm1d/tm2) nuclear extracts (Figure 2B). The Setdb1 tm2
allele removes exon 4 to induce a frameshift that is pre-
dicted to lead to 353 aa product, consistent with an ob-
served 39 kDa truncation product in extracts containing
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this mutant allele (Figure 2B). The truncation occurs within
the N-terminal Tudor domain (53) and the mutant product
is missing the methyl-CpG DNA-binding motif, pre-SET
and SET domains (54); therefore, the truncation product
is expected to be non-functional. GFP expression from the
tm2 allele is detectable in these cells, as expected (Supple-
mentary Figure S5b and c). To test whether Setdb1 is an
essential gene in ES cells, we performed stringent growth
assays. Setdb1 null mutant cells are unable to form nor-
mal ES cell colonies under clonal growth conditions (Fig-
ure 2C) and exhibit a severely impaired growth rate (Fig-
ure 2D). In bulk culture, Setdb1 null ES cells appear nor-
mal up to 4 days after starting 4′OHT treatment, exhibit-
ing strong alkaline phosphatase (AP) activity (Figure 2E),
high levels of the pluripotency transcription factor Oct4
(also known as Pou5f1) protein expression and global hi-
stone H3K9 trimethylation (me3) (Supplementary Figure
S5d). However by day 6, Setdb1 tm1d/tm2 ES cells begin
to exhibit a flattened morphology and are mostly differen-
tiated by day 8, with very few AP positive cells remaining
(Figure 2E). As with any inducible system, there is a pos-
sibility that a small number of non-recombined ‘escaper’
cells (genotype tm1c/tm2) remain following 4′OHT treat-
ment when most cells are expected to have been converted
to genotype tm1d/tm2. Based on our Setdb1mutant ES cell
colony assay data (Figure 2C), we estimate having <1 in
1000 ‘escaper’ cells, since we rarely observed a normal ES
colony (dense core of tightly packed cells strongly staining
with methylene blue which would likely represent the non-
recombined tm1c/tm2 genotype) appearing after plating
1000 single 4′OHT treated cells in our replicates. To ensure
that all cells in the culture have a tm1d/tm2 genotype, for
non-essential genes, we recommend that researchers sub-
clone their cell lines following 4′OHT treatment prior to
performing downstream assays.
Gene expression and ChIP-seq analysis of inducible condi-
tional Setdb1 mutant ES cell lines
To further gain insight into Setdb1 function, we assessed
changes in gene expression by DNA microarray analysis
and H3K9me3 chromatin marks genome-wide by ChIP-
seq, over a 6 day 4′OHT timecourse of experimentally ab-
lated and control Setdb1 ES cells (Figure 3). Experimen-
tal and control mutant Setdb1 ES cells were treated with
4′OHT for 48 h, while gene expression was analysed at days
0 (before treatment), 2 (end of treatment), 3, 4 and 6. Before
4′OHT treatment there were very few significant changes in
gene expression between the experimental (tm1c/tm2) and
control (tm1c/+) Setdb1ES cells, with only one gene, Setdb1
itself, expressed at a lower level in the experimental cells
as expected and 8 genes expressed at a higher level in the
experimental cells (Supplementary Table S7). However, by
day 2 after the start of 4′OHT treatment, there were 1331
genes showing significant changes in expression between the
experimental null (tm1d/tm2) and control (tm1d/+) Setdb1
ES cells, with roughly equal numbers of upregulated and
downregulated genes. By day 6, 7848 genes had significant
expression changes, with slightly higher number of genes
downregulated as opposed to upregulated in the experimen-
tal (tm1c/tm2) null ES cells (P< 0.05; Supplementary Table
S7).
We assessed changes in gene expression of pluripo-
tency and differentiation markers (Figure 3A) and chro-
matin or epigenetic regulatory factors (Figure 3B). Many
pluripotency factors and markers (e.g. Nanog, Esrrb, Sox2,
Pou5f1/Oct4) show a gradual downregulation in the exper-
imental null Setdb1 ES cells compared to the control ES
cells over time, and by day 6 most of these were signif-
icantly and strongly downregulated. Several differerentia-
tion markers for multiple lineages including trophectoderm
(e.g. Cdx2) were significantly strongly upregulated by the
end of the timecourse. We also observed upregulation of
some imprinted loci (e.g. Mest, H19 and Igf2r), suggesting
that DNAmethylation imprints are lost at these loci. Anal-
ysis of expression of chromatin factors (Figure 3B) also re-
vealed significant changes, including in two DNA methyl-
transferases (Dnmt1 andDnmt3b) and other H3K9 methyl-
transferases (G9a/Ehmt2/Bat8 and GLP/Ehmt1), again
occurring mainly towards the end of the timecourse. Con-
sistent with our phenotypic observations, among the cohort
of genes downregulated early on (in day 2 dataset) follow-
ing Setdb1 ablation were those associated with GO terms
for stem cell maintenance, negative regulation of cell differ-
entiation, regulation of embryonic development, and posi-
tive regulation of cell proliferation (Figure 3C). We identi-
fied a different set of enriched GO terms among the cohort
of upregulated genes, notably relating to chromatin assem-
bly, and chromosome organization or segregation. The GO
terms of negative regulation of cell cycle and regulation of
cell fate specification from this cohort are consistent with
our phenotypic observation of reduced growth of ES cells
following Setdb1 ablation.
Setdb1 is known to trimethylate histone H3 on lysine
9 and this correlates with its repressive function using a
reconstituted chromatin transcriptional activation system
(55,56). Although we found no change in bulk H3K9me3
levels in Setdb1 null ES cells (Supplementary Figure S5d),
we looked for locus-specific alterations of H3K9me3 us-
ing ChIP coupled with massively parallel DNA sequenc-
ing (ChIP-seq) over a timecourse in 4′OHT treated Setdb1
null ES cells versus control ES cells. We found progressive
reductions in H3K9me3 at many known targets of Setdb1
(57–60), including imprinted genes (e.g.H19), olfactory re-
ceptors (e.g.Olfr901), trophoblast development factors (e.g.
Cdh3) (Figure 3D and Supplementary Figure S6a). In our
profiling, 67 and 86% respectively, of the Setdb1-regulated
H3K9me3 sites previously identified by Bilodeau et al. (57)
and Yuan et al. (60) using RNAi knockdown of Setdb1 in
mouse ES cell lines, show>1.5-fold reduction of H3K9me3
6 days after 4′OHT induction. Even by 2 days after in-
duction, 35% of the H3K9me3-reduced sites identified by
Yuan et al. (60) show H3K9me3 reduction in our experi-
ments, identifying these regions as rapidly affected targets
of Setdb1. We also observed a prominent loss of H3K9me3
over endogenous retroviral elements following Setdb1 ab-
lation (Figure 3E and Supplementary Figure S6b) and at
additional gene loci (Supplementary Figure S6c). To take
potential antibody crossreactivity into account, results were
confirmed with three different H3K9me3 antibodies (Sup-
plementary Figure S6a–c).
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Figure 3. Timecourse analyses of gene expression and H3K9me3 histone modification marks in inducible conditional Setdb1 tm1c/tm2 mutant ES cells
compared to control Setdb1 tm1c/+ ES cells following 4′OHT treatment and conversion of the conditional tm1c allele to the null tm1d allele. (A) Heatmap
of changes in gene expression of pluripotency associated genes, lineage markers and imprinted genes by DNA microarray, following Setdb1 ablation. (B)
Heatmap shows complex changes in expression of chromatin and epigenetic factors, in Setdb1 null ES cells. Key to log-fold-change values are below each
heatmap. Negative values, indicating downregulation in Setdb1 null ES cells, are shown in yellow; positive values, indicating upregulation in Setdb1 null
ES cells, are shown in blue. (C) GO Biological Processes analysis of up- or downregulated genes at a single timepoint early after Setdb1 ablation in ES cells.
Categories enriched in Setdb1 tm1d/tm2 mutant versus +/tm1d control ES cell gene expression datasets after a 2-day 4′OHT treatment (same datatset as
day 2 in heatmaps) are shown. White bars represent the number of genes observed while black bars represent the number of genes expected by chance in
each GO category (P< 0.02). (D) ChIP-seq H3K9me3 profiles at selected loci in Setdb1 tm1c/tm2mutant ES cells at timepoints before and following a 48
h 4′OHT treatment. T = 0, untreated cells at start of timecourse; T = 2d/4d/6d, 2/4/6 days after start of 4′OHT treatment. (E) The percentage of reads
present on endogenous retrovirus repeats (ERVs) or Alu repeats during the same timecourse as in (D), * indicates sample significantly different to T = 0
sample, P < 0.01 (Fisher’s Exact test) with the additional requirement of >1.5-fold change between the profiles.
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Effect of enhancing pluripotency-promoting conditions on the
growth of inducible conditional Setdb1 mutant ES cell lines
Given the striking decrease in expression of pluripotency
associated genes and increase in differentiation associated
genes following Setdb1 depletion in ES cells, we sought to
determine whether forced promotion of pluripotency con-
ditions in the absence of Setdb1would rescue the growth re-
duction phenotype. To this end, we adopted two experimen-
tal approaches. The first was introducing a constitutively ac-
tiveNanog (61) transgene (+Ng) into the genome of Setdb1
tm1c/tm2mutant ES cells and into JM8WTES cells as con-
trols and monitoring growth and expression of key pluripo-
tency and differentiation genes upon Setdb1 ablation (Fig-
ure 4 and Supplementary Figure S7). We reconfirmed geno-
types of clones with theNanog transgene using our existing
genomic PCR assays (Supplementary Figure S7a and b).
Immunofluorescence microscopy showed that Nanog ex-
pression was maintained in the majority of +Ng Setdb1
tm1d/tm2 null ES cells for at least 7 days after 4′OHT
treatment of Setdb1 tm1c/tm2 mutant ES cells, whereas
in Nanog-untransfected parental Setdb1 tm1d/tm2 null ES
cells under the same treatment very few Nanog express-
ing cells were detectable, consistent with Nanog mRNA
downregulation observed in our gene expressionmicroarray
timecourse analysis (Supplementary Figure S7c and Figure
3A). Enforced Nanog expression was unable to rescue the
growth defect of Setdb1 tm1d/tm2 null ES cells (Figure 4A)
and these cells are unable to form ES cell colonies (Figure
4B), whereas control JM8 WT ES cells (with or without
the Nanog transgene) cultured concurrently show robust
growth characteristics. Strikingly, in +Ng Setdb1 tm1d/tm2
null ES cells (post-4′OHT treatment), in which Nanog ex-
pression is restored as expected, expression of Oct4 and
Rex1 returns to levels similar or higher than those in WT
and derepression of Cdx2 is substantially diminished (Fig-
ure 4C). As an independent test of enhancing pluripotency-
promoting conditions on growth of Setdb1mutant ES cells,
we cultured Setdb1mutant and control ES cells in LIF plus
ground state pluripotency ‘two-inhibitor’ (2i) media (2,45)
and reconfirmed clone genotypes by PCR (Supplementary
Figure S8a). Setdb1 tm1d/tm2 null mutant ES cells grown
in 2i+LIF also exhibit a severely impaired growth rate sim-
ilar to that in serum+LIF conditions (Supplementary Fig-
ure S8b) and cannot form undifferentiated ES cell colonies
(Supplementary Figure S8c), despite having uniformly high
levels of Nanog expression throughout the culture (Supple-
mentary Figure S8d). We conclude that neither of the two
naive pluripotency-promoting conditions (Nanog transgene
expression or 2i+LIF culture) tested are able to rescue the
severe self-renewal defect in ES cells upon Setdb1 ablation.
DISCUSSION
The modular design of IKMC Intermediate Vectors from
the extensive KOMP-CSD and EUCOMM mouse knock-
out project resources (31,35) provides a flexible platform
for engineering a wide variety of useful alleles using both
replacement and insertional gene targeting strategies. Here
we have utilized this resource to develop an insertion-type
targeted trapping vector (pI hygGFP) and use it to consti-
tutively inactivate the second allele in existing IKMC het-
erozygous ‘knockout-first’ mutant mouse ES cells, thereby
generating bi-allelic null ES cells for the gene of inter-
est. Making a pI hygGFP vector for a gene with an In-
termediate Vector represented in the IKMC resource is
amenable to non-specialists in vector design, since all of
the modules required for building the final targeting vec-
tor already exist. The pI hygGFP targeting vector is assem-
bled in vitro in a three-way Gateway™ exchange reaction
between the IKMC Intermediate Vector and two purpose
built vector modules that we designed: an adaptor module
(pL1L2 RloxP) and the appropriate reading frame version
of the hygromycin-GFP gene trap vector (pL3L4 hygGFP).
The pI hygGFP vector is introduced, typically by electro-
poration, into an IKMC heterozygous ‘knockout-first con-
ditional ready’ (containing the tm1a allele) mutant ES cell
line, and clones are screened by PCR based genotyping to
isolate bi-allelic null ES cell lines for the gene of interest.
Our strategy is highly efficient for the generation of bi-allelic
null mutant mouse ES cells, incorporates a GFP marker in
the second (tm2) allele and can potentially be applied to
thousands of mutant ES cells in the public IKMC resource
from the KOMP-CSD and EUCOMM pipelines, contain-
ing heterozygous null mutations in expressed genes.
We observe a high average frequency of bi-allelic targeted
clone recovery of 60% for 11 genes expressed in ES cells. A
novel design feature of our ‘second allele’ targeting strategy
is that the hygromycin selectable marker is not activated in
clones that have re-targeted the ‘knockout-first’ (tm1a) al-
lele (in trans), hence re-targeting of the existing ‘knockout-
first’ mutant allele is selected against. The high targeting ef-
ficiency of our system reflects the combined effects of us-
ing: (i) insertion-type targeting vectors that are intrinsically
more efficient than replacement-type vectors (4,62); (ii) ‘tar-
geted trapping’ cassettes that enrich for correctly targeted
events (10,35); and (iii) preferential recovery of second al-
lele (in cis) targeting events by direct drug selection. Our
method is also time efficient as the number of electroporated
colonies required for screening to obtain the desired event
is low; we routinely screened 24 clones per targeting exper-
iment. Furthermore, this approach can be used to identify
essential genes in ES cells. Provided that the targeting ability
of the pI hygGFP vector is validated inWTES cells, the ab-
sence of colonies upon appropriate drug selection following
targeting with the pI hygGFP vector of IKMC heterozy-
gous cells already containing the ‘knockout-first’ (tm1a) al-
lele indicates that the gene is required for ES cell survival.
To enable further studies and extend the usefulness of re-
sources generated by the IKMC project, we set out to in-
vestigate the function of chromatin or epigenetic factors ex-
pressed in ES cells as proof of principle of our bi-allelic gene
targeting approach. ES cells have been successfully used as a
model system to investigate chromatin structure and func-
tion (63–65). We generated bi-allelic mutant ES cell lines
for 11 epigenetic regulators, andwe identified three essential
genes in ES cells: Ddx27, Phf20 and Setdb1. Two of our bi-
allelic mutant ES cell lines, for the Jarid2 and Jmjd2c (also
known as Kdm4c) genes, have been used in separate stud-
ies to further investigate regulation of epigenetic factors on
pluripotency and differentiation (52,66).
For viable null mutant ES cells displaying a phenotype,
the ability to perform genetic reversion experiments is the
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Figure 4. Effect of enhancing pluripotency-promoting conditions by constitutively expressing transgenic Nanog (+Ng) on inducible conditional Setdb1
mutant ES cell lines. (A) Growth of Setdb1 tm1d/tm2 mutant +Ng ES cells remains compromised, while control wild-type (WT) JM8 ES cells (without
or +Ng) show robust growth characteristics. Cells were plated following a 48 h 4′OHT treatment and counted at the time intervals indicated. Results
show the mean with error bars indicating the s.d. of three independent experiments. Data shown are from one representative cell line per genotype; similar
results were obtained using three additional independent cell lines per genotype. (B) Setdb1 tm1d/tm2 mutant +Ng ES cells plated at low density remain
unable to form normal sized colonies of undifferentiated ES cells, whereas 4′OHT treated control WT JM8 ES (without or +Ng) cells generate robust ES
cell colonies. Cells were stained with methylene blue 8 days after plating on 10 cm tissue culture dishes. (C) Analysis of gene expression by quantitative
RT-PCR at indicated timepoints before and following a 48 h 4′OHT treatment of Setdb1 tm1c/tm2 (becoming tm1d/tm2 after treatment) mutant ES cells
(Setdb1 mutant) and control JM8 ES cells (WT), each +Ng, compared to the respective parental cell lines without the Nanog transgene. Results show
mean ± s.d. of three independent experiments; asterisks indicate statistically significant differences between sample groups indicated with a bar (*, P <
0.025, **, P < 0.01; two-tailed Student’s t-test).
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preferred method for establishing causality, as it offers a
more precise and less invasive way to reinstate gene expres-
sion, due to the resulting minimal sequence changes in-
troduced in the genome than BAC or cDNA-based trans-
genic approaches which may confound the rescue pheno-
type. Through the action of Flp recombinase we generated
revertant ES cells from our viable Jarid2 and Cbx1 null
tm1a/tm2 mutant ES cells, confirmed reappearance of the
full length protein, and investigated gene expression profiles
by microarray in the null mutants compared to revertant
ES cell lines. Cbx1 is one of three mammalian Heterochro-
matin Protein 1 homologs that bind pericentromeric and
telomeric heterochromatin, and a different Cbx1 constitu-
tive knockoutmousemodel exhibited perinatal lethality due
to a defect in neuromuscular development (67). However,
consistent with a later study (68), there was no increased
tendency of Cbx1 null ES cells to differentiate during our
routine cell culture. The paucity of gene expression changes
upon reversion of ourCbx1 null to heterozygous mutant ES
cells is consistent with the absence of an overt phenotype in
Cbx1 null ES cells. Jarid2 belongs to the Jumonji histone
lysine demethylase family and is a component of the PRC2
Polycomb repressive complex in ES cells which confers hi-
stone H3K27 trimethylation (69). In a separate study (52),
our Jarid2 null ES cells were shown to be severely compro-
mised in multi-lineage differentiation and their ability to in-
duce lineage-specific gene expression in vitro upon receipt of
differentiation cues, concordant with a lack of recruitment
of Polycomb PRC1 complexes and failure in establishing
poised RNA Polymerase II at PRC2 target genes. The find-
ings from our gene expression analyses comparing null to
revertant Jarid2ES cells are consistent with previous studies
comparing WT to Jarid2 null mutant or RNAi knockdown
ES cells (52,70–73), in that we identified aberrant expres-
sion of targets of Suz12 (a PRC2 component) and histone
H3K27-trimethylated genes, as well as enrichment of GO
categories relating to cell differentiation and developmen-
tal pathways and RNA polymerase II transcription factor
activity.Wedemonstrated functional reversion of amolecu-
lar phenotype in our revertant Jarid2 tm1c/tm2 ES cells, by
showing restored recruitment of the Polycomb PRC1 com-
ponent Mel18 at PRC2 target gene promoters, thereby con-
firming causality and providing a relevant example of the
efficacy of our genetic reversion system.
During the course of our gene targeting experiments, we
identified three putative essential genes in ES cells includ-
ing Setdb1, through our inability to recover bi-allelic tar-
geted clones while the individual pI hygGFP vectors read-
ily targeted WT ES cells. The flexibility of the IKMC al-
lele structure allows for creation of inducible conditional
mutant ES cells, which we demonstrated for Setdb1 using
our pI hygGFP vector to constitutively inactivate one allele
while conditionally inactivating the other allele, as further
proof of principle of our system, and which allowed us to
explore Setdb1 function in regulating pluripotency and self-
renewal in detail. Setdb1 is a histone H3K9 methyltrans-
ferase that can act as a transcriptional repressor (55,56).
Zygotic Setdb1 ablation in mice leads to peri-implantation
lethality and inability to derive de novo ES cells from in-
ner cell mass cells (74). These observations are consistent
with our inability to generate Setdb1 constitutive null ES
cells by sequential gene targeting of ES cells. The pheno-
type of our inducible conditional Setdb1 null ES cells fol-
lowing 4′OHT treatment agrees well with published Setdb1
shRNA knock down and conditional null ES cell studies, as
we have shown promiscuous differentation, a severe growth
defect, and locus-specific reductions in H3K9me3 marks at
many Setdb1 target genes and some endogenous retrovirus
elements (57–60,75–77). Our results strongly suggest that
Setdb1 is required to maintain both self-renewal and the
pluripotent state in ES cells.
Our approach enabled time-course studies of Setdb1
gene ablation induced by 4′OHT treatment, minimized ge-
netic differences between the control and experimental cell
lines, while importantly also controlling for the effect of
4′OHT by treating both the control and experimental sam-
ples concurrently, advantages which are lacking in several
earlier Setdb1 studies in ES cells (57,59,60). We observed
progressively reduced expression of pluripotency factors,
along with increased expression of differentiation markers
of all three germ layers and also trophectoderm, germline,
and imprinted genes, after Setdb1 ablation over a 6 day
timecourse, which broadly agrees with previous analyses
(58,60). Our Setdb1 ablation day 2 timecourse set of up-
regulated genes showed enrichment for GO terms relat-
ing to chromatin assembly and chromosome organization
and segregation, consistent with previous work demon-
strating Setdb1 requirement for proper spindle organiza-
tion in oocyte maturation (78) and role in re-establishing
pericentric heterochromatin during DNA replication (79).
Previous reports (57–60) and our data suggests that re-
pression of pluripotency gene pathways could lead to the
growth and differentiation defects observed in Setdb1 de-
pleted ES cells. To address this issue, we chose to fur-
ther apply our pI hygGFP vector targeted inducible con-
ditional mutant Setdb1 ES cells to tease apart the roles of
Setdb1 in regulating pluripotency, differentiation, and self-
renewal, by experimentally enforcing ground state pluripo-
tency on Setdb1 ablated ES cells and asking if this would
rescue any aspect of the Setdb1 ablation phenotype. We
utilized two approaches; the first, to introduce a constitu-
tively activeNanog transgene into the genome of Setdb1 in-
ducible mutant ES cells; the second, by culturing the cells
in ‘two-inhibitor’ (2i) containing media, which captures
ES cells in the ground state of pluripotency by suppress-
ing the Gsk3 and Fgf-MAPK differentiation-promoting
signalling cascades, leading to homogenous high levels of
Nanog expression (2,45,61). Nanog is a key pluripotency
regulator (61,80–84), the Nanog locus is a direct target of
Setdb1 (57,60), ES cells are not overly sensitive to dosage-
related differentiation induction from altered expression of
Nanog compared to that of other key pluripotency factors
(85,86) andNanogwas one of the most rapidly and strongly
downregulated genes among the pluripotency factors upon
Setdb1 ablation in ES cells according to our gene expression
timecourse analysis.
Interestingly, while Nanog mRNA and protein expres-
sion remained homogenous and at high levels as ex-
pected under both pluripotency-promoting conditions we
tested, neither condition was able to rescue the severe self-
renewal/growth defect upon Setdb1 ablation in ES cells.
Pluripotency is maintained by a genetic regulatory net-
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work centered around the core transcription factors Oct4,
Sox2 and Nanog, which coordinately directly activate their
own gene expression and repress activity of lineage-specific
transcription factors, thereby suppressing differentiation
(61,80). Oct4 acts in a mutually repressive direct regula-
tory feedback loop with Cdx2 to distinguish between em-
bryonic and extraembryonic lineages (85,86). Setdb1 de-
pleted ES cells show an enhanced ability to differentiate
along the trophoblast lineage and derepress the trophecto-
derm differentiation factor Cdx2, which has been identified
as a direct target of Setdb1 by ChIP analysis (58–60). Previ-
ous studies suggested that Setdb1maintains pluripotency in
part through direct repression of Cdx2 via interaction with
Oct4 that is dependent on SUMOylation of Setdb1 and sup-
port a view that derepression of Cdx2 in Setdb1 depleted
ES cells and blastocysts is directly due to a loss of Setdb1-
dependent H3K9 methyation rather than a secondary con-
sequence of Oct4 depletion (58–61,86). While our gene ex-
pression results confirm derepression of Cdx2 in Setdb1
ablated ES cells, we surprisingly found no evidence of al-
teredH3K9me3 at theCdx2 locus in our ChIP-seq analyses.
Enforcing constitutive expression of Nanog in the absence
of Setdb1 in ES cells led to restoration of gene expression
of the pluripotency transcription factor Oct4 and marker
Rex1, and further led to a striking reduction of Cdx2 dere-
pression to near normal (low to absent) expression levels.
These results suggest that (i) pluripotency can be rescued
in the absence of Setdb1 gene expression by over-riding
Setdb1-mediated Nanog downregulation, and (ii) misregu-
lation of Cdx2, and therefore restriction of trophoblast lin-
eage potential in ES cells, is primarily influenced by direct
loss of Nanog following Setdb1 depletion rather than via
direct regulation by Setdb1, as previously suggested (59).
Collectively, our results strongly suggest that Setdb1 regula-
tion of pluripotency is mediated primarily through its direct
action in maintaining normal expression levels of Nanog.
Setdb1 regulation of proliferation/self-renewal is likely me-
diated through a separate pathway than its regulation of
pluripotency, rather than the reduction in growth rate being
a secondary consequence of increased differentiation aris-
ing from exiting the pluripotent state following Setdb1 de-
pletion.
To assist users in successfully applying our bi-allelic tar-
geting strategy to their gene(s) of interest, we discuss addi-
tional applications, potential caveats, and important qual-
ity control measures. We validated our second allele tar-
geting strategy in IKMC tm1a/+ ES cells generated with
a ‘knockout-first’ promoterless vector. As an extension of
applications using our pI hygGFP vector, we note that
other classes of heterozygous null mutant ES cells from
the IKMC resource should be amenable to our targeting
strategy to generate bi-allelic null ES cells, provided that
the gene is expressed at a sufficiently high level to enable
effective hygromycin selection. All KOMP-CSD and EU-
COMM ‘knockout-first’ vectors, both promoterless and
promoter-driven, were constructed from Intermediate Vec-
tors of the same format, it is the Gateway-adapted plas-
mids used for the final assembly step in the high-throughput
vector construction pipeline which differ (35), and hence it
is possible to construct a pI hygGFP insertion vector for
any Intermediate Vector. In total, there are 16 296 vec-
tor designs for first allele targeting (including promoterless
and promoter-driven vectors) representing 15 185 different
genes within the IKMC resource, collectively produced by
the KOMP, EUCOMM and NorCOMM projects (http://
www.mousephenotype.org/about-ikmc); this resource con-
tains ES cells with mutant alleles for expressed and non-
expressed genes, and a variety of first mutant allele types
(31,33,35). Expressed genes represented by heterozygous
mutant ES cells containing the EUCOMM or KOMP-
CSD ‘promoter-driven selection cassette’ class tm1a al-
lele, tm1e/+ ‘targeted non-conditional’ allele containing ES
cells, and tm1/+ or tm1.1/+ ‘targeted deletion’ ES cells,
should be amenable to bi-allelic targetingwith a pI hygGFP
vector. Our strategy will not work in conjuction with de-
signs from the KOMP-Regeneron project as they utilized
a different vector construction pipeline in which there are
no Intermediate Vectors (31). Detailed information on all
IKMC produced vectors and alleles are available through
the IKMC Targeting Repository at the IMPC web portal
(33) (https://www.mousephenotype.org/imits/targ rep).
We expect that a threshold of gene expression level
will exist to permit successful targeted trapping using our
pI hygGFP vector. Although we have not quantified the
lower threshold, a separate study using different targeted
trapping vectors was able to define aminimum threshold for
success as 1% of the expression level of the ‘housekeeping’
transferrin receptor (Trfr) gene, and reported a high suc-
cess rate for genes expressed at >5% of Trfr (10). Another
indicator of high probability for success of pI hygGFP vec-
tor targeted trapping into other classes of heterozygous
null mutant ES cells from the IKMC projects is that the
gene of interest has previously been gene trapped, which
can be checked against the International Gene Trap Con-
sortium database (7) (http://www.genetrap.org/). We advise
researchers interested in applying our bi-allelic targeting
method to classes of first mutant alleles other than those
madewith IKMCpromoterless vectors to confirm that their
gene of interest is expressed above 1% Trfr level in ES cells
and/or has been gene trapped, prior to ordering the relevant
Intermediate Vector from the IMPC for pI hygGFP vector
construction.
Our approach assumes that the IKMC tm1a alleles
(31,35) and tm2 alleles are null alleles. The EUMODIC and
Sanger Institute MGP large-scale mouse phenotyping pilot
projects successfully used the tm1a allele to generate over
600 mutant mouse lines and noted that this design gave
rise to null alleles for most genes (38,39,87). However in
some cases, failure of complete transcription stop at the in-
serted vector cassette occurred, in which case the tm1a al-
lele led to a knockdown of gene expression (87). Recogniz-
ing this, subsequent and ongoing phenotyping programmes
within the IMPC are producing mutant mice from the Cre-
recombined tm1b allele, in which removing a ‘critical exon’
is designed to induce a frame-shift mutation (35), as an ex-
tra precaution to increase the probability of generating a
null allele (40,41,88). Should the tm1a allele for an ES cell
expressed gene of interest prove to be inadequate, our strat-
egy for second allele targeting with the pI hygGFP vector
can also be applied to tm1b/+ ES cells; however, the tm1b
null allele is not revertible nor drug-selectable. The design
of the tm2 allele, as for the tm1a allele, relies on an intro-
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duced stop codon in the trapping cassette to terminate tran-
scription, thus there is a risk that splicing over or incomplete
termination could occur. As with any gene modification ap-
proach, researchers must carefully validate each allele and
mutant ES cell line prior to use in functional studies.
The EUCOMM and KOMP-CSD vector construction
and gene targeting pipelines were high-throughput, and
therefore ES cell clones from the resource were genotyped
for correct targeting by PCR only (35). Analysis of 9496
IKMC vector gene targeting events revealed that the pro-
portion of clones with random integrations was 2.1% (25).
Given the possibility of complex vector integration events
or random integrations, we recommend that researchers
use additional methods (e.g. Southern blot with an exter-
nal probe) to verify proper targeting of the intended al-
lele prior to extensive use of bi-allelic mutant ES cells in
functional studies. To detect the presence of random vector
integrations into the genome, Southern blot with a probe
from the selectable marker or vector cassette, or methods to
measure copy number variation such as quantitative PCR
(e.g. droplet digital PCR), could be applied. Ryder et al.
(38) found that of 731 EUCOMM or KOMP-CSD ES cell
clones achieving germline transmission, 86% passed qual-
ity control (QC) testing and the failures were typically due
to having mixed ES cell clones. Mixed clones can readily be
resolved through subcloning and re-screening a number of
subcloned lines.
We recommend that researchers perform QC checks on
control and mutant ES cells, including assessing chromo-
some integrity and pluripotency status. ES cells should ide-
ally be QC checked throughout their period in culture,
as abnormalities could develop over extended time in cul-
ture. Chromosome integrity can be monitored by karyotyp-
ing or analysis of copy number variation. Standard indi-
cators of pluripotency of mouse ES cell lines include pos-
itive staining for AP activity and expression of core and
naı¨ve pluripotency markers including Oct4, Sox2, Nanog,
Esrrb, Klf2/4 and Tfcp2l1 (2). The defining test of pluripo-
tency is the ability of the cell to contribute to all devel-
opmental lineages in a chimeric embryo following intro-
duction into a host blastocyst and be germline compe-
tent. Germline transmission rates of EUCOMMvector tar-
geted JM8, JM8.N4 and JM8.F6 mouse ES cell clones
ranged from 62–69% (44) and current germline transmis-
sion rates for targeted KOMP-CSD ES clones in these
same genetic backgrounds range from 59 to 66% (https://
www.komp.org/gltrates2.php). Prior to ordering clones, we
recommend checking the IMPC web portal (https://www.
mousephenotype.org) to determinewhether the researcher’s
allele of interest has undergone germline transmission and
passed IMPC QC screening, in order to request the high-
est quality clones. For alleles with no germline transmis-
sion data, we recommend that users QC test up to three
ES cell clones (tm1a/+) from IKMC/IMPC repositories
in order to obtain at least one that passes QC for use in
bi-allelic targeting. For the phenotyping experiments per-
formed in this study we used a minimum of three inde-
pendent clones of each genotype (biological replicates) of
bi-allelic targeted ES cells, rather than relying on technical
replicates. In this way, stringency is increased and the im-
pact of any one clone having off-target or other genetic de-
fects is minimized. However the final choice of the number
of independent clones used will be driven by the research
hypothesis, study design, and statistical methods employed.
In summary, our work demonstrates the feasibility of
performing gene ablation and genetic reversion experi-
ments, using existing vectors and gene targeted heterozy-
gous ‘knockout-first’ tm1a/+ mutant mouse ES cells which
are readily available from IKMC/IMPC public resources,
combined with our new insertional targeted trapping
pI hygGFP vectors for bi-allelic gene targeting of expressed
genes to rapidly and efficiently generate null ES cells. Our
approachwas applied as proof of principle to investigate the
function of chromatin and epigenetic regulators including
Jarid2 and Cbx1, and can be applied to identify genes es-
sential for basic cellular and developmental processes using
mouse ES cells. Application of our technology for the gen-
eration of inducible conditional mutant ES cell lines, such
as we have illustrated for Setdb1, will facilitate further in-
vestigations of essential genes in both undifferentiated ES
cells and in vitro cell differentiation models. Rapid produc-
tion of bi-allelic null mouse ES cells using our method,
which builds upon existing and extensive IKMC resources,
will enable their use in a wide range of gene function stud-
ies, validating and complementing current approaches us-
ing genome-editing technology which has a higher propen-
sity of off-target effects. Our method for bi-allelic targeting
maximizes usage of cost-efficient readily available IKMC
resources and will further enable the use of mouse ES
cells as a model system for fundamental investigations of
pluripotency and differentiation pathways and studies in re-
generative medicine.
DATA AVAILABILITY
Information on all available Intermediate Vectors and
targeted ES cells from the EUCOMM and KOMP-
CSD mutant mouse resource projects generated by the
IKMC can be obtained via the IMPC website at http://
www.mousephenotype.org/. IKMC Intermediate Vectors,
‘knockout-first, conditional ready’ and other IKMC final
targeting vectors, JM8 WT and heterozygous ‘knockout-
first, conditional-ready’ (tm1a/+) mutant ES cells can be
ordered from IMPC public repositories via the IMPC web
portal (http://www.mousephenotype.org). Plasmids gener-
ated in this study will be available from Addgene (https:
//www.addgene.org/).
Microarray gene expression data have been deposited in
the ArrayExpress database at EMBL-EBI (www.ebi.ac.uk/
arrayexpress) under accession numbers E-MTAB-5930 for
Jarid2 andCbx1, and E-MTAB-5931 for Setdb1mutant ES
cell experiments respectively. All ChIP-seq data (FASTQ,
BED and WIG files) are present in the NCBI GEO Super-
Series GSE31777.
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Supplementary Data are available at NAR Online.
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